{
    "organizations": [],
    "uuid": "2a2f78c8af8ef0a3368571527e54db4e506e2ee1",
    "author": "Jan Wolfe",
    "url": "https://www.reuters.com/article/ip-patent-vanda/patent-on-vanda-schizophrenia-drug-upheld-by-appeals-court-idUSL1N1RQ28F",
    "ord_in_thread": 0,
    "title": "Patent on Vanda schizophrenia drug upheld by appeals court",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "A federal appeals court on Friday ended a bid by West-Ward Pharmaceuticals Corp to invalidate a patent on Vanda Pharmaceutical Inc’s schizophrenia drug Fanapt and bring a lower-cost generic version to market.\nThe U.S. Court of Appeals for the Federal Circuit upheld a lower court ruling that a Vanda patent describing a method of using Fanapt to treat schizophrenia was valid and would be infringed by West-Ward’s proposed generic.\nTo read the full story on Westlaw Practitioner Insights, click here: bit.ly/2GZ3UDM\n ",
    "published": "2018-04-14T07:13:00.000+03:00",
    "crawled": "2018-04-14T13:23:23.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "federal",
        "appeal",
        "court",
        "friday",
        "ended",
        "bid",
        "pharmaceutical",
        "corp",
        "invalidate",
        "patent",
        "vanda",
        "pharmaceutical",
        "inc",
        "schizophrenia",
        "drug",
        "fanapt",
        "bring",
        "generic",
        "version",
        "market",
        "court",
        "appeal",
        "federal",
        "circuit",
        "upheld",
        "lower",
        "court",
        "ruling",
        "vanda",
        "patent",
        "describing",
        "method",
        "using",
        "fanapt",
        "treat",
        "schizophrenia",
        "valid",
        "would",
        "infringed",
        "proposed",
        "generic",
        "read",
        "full",
        "story",
        "westlaw",
        "practitioner",
        "insight",
        "click"
    ]
}